Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Net Income (2024 - 2025)

Silence Therapeutics' Net Income history spans 2 years, with the latest figure at -$3.7 million for Q4 2025.

  • For Q4 2025, Net Income fell 120.94% year-over-year to -$3.7 million; the TTM value through Dec 2025 reached -$82.3 million, down 99.41%, while the annual FY2025 figure was -$68.2 million, 53.35% down from the prior year.
  • Net Income for Q4 2025 was -$3.7 million at Silence Therapeutics, up from -$26.2 million in the prior quarter.
  • Across five years, Net Income topped out at $17.7 million in Q4 2024 and bottomed at -$30.0 million in Q3 2024.